To ask the Secretary of State for Health and Social Care, what discussions he has had with manufacturers of Pancreatic Enzyme Replacement Therapy medication on supply shortages.

The Department is in regular discussion with all suppliers of pancreatic enzyme replacement therapy (PERT) on latest stock availability and the actions that are being taken mitigate the supply issue that is affecting the whole of the United Kingdom. Through these discussions we have managed to secure additional volumes of PERT for 2025 for the UK. We are continuing to work with all suppliers to understand what more can be done to add further resilience to the market. The Department has also reached out to specialist importers who have sourced unlicensed stock to assist in covering the remaining gap in the market.

In the longer term, the Department has had interest from non-UK suppliers wishing to bring their products to the UK and, along with colleagues in the Medicine and Healthcare products Regulatory Agency, we are working with these potential suppliers; if authorised these products could further diversify and strengthen the market.